KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Non Operating Income (2021 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Non Operating Income for 5 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 36.51% to $5.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $28.2 million, a 31.07% decrease, with the full-year FY2025 number at $28.2 million, down 31.07% from a year prior.
  • Non Operating Income was $5.0 million for Q4 2025 at Xenon Pharmaceuticals, down from $6.1 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $11.5 million in Q1 2024 to a low of -$2.7 million in Q1 2022.
  • A 5-year average of $6.1 million and a median of $7.6 million in 2023 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: soared 1706.91% in 2023, then plummeted 42.11% in 2025.
  • Xenon Pharmaceuticals' Non Operating Income stood at -$52000.0 in 2021, then skyrocketed by 13705.77% to $7.1 million in 2022, then rose by 23.63% to $8.7 million in 2023, then fell by 9.18% to $7.9 million in 2024, then tumbled by 36.51% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Non Operating Income are $5.0 million (Q4 2025), $6.1 million (Q3 2025), and $8.9 million (Q2 2025).